Written and maintained by CASRAI Editorial Board
Last updated
The GAD-7 scale (Generalized Anxiety Disorder 7-item scale) is one of the most widely validated patient-reported outcome measures (PROMs) in primary care, psychiatry, behavioral health, and clinical trial research for screening and tracking anxiety symptom severity. Developed and validated by Robert L. Spitzer, MD, Kurt Kroenke, MD, Janet B. W. Williams, DSW, and Bernd Löwe, MD, PhD, in Archives of Internal Medicine (2006;166(10):1092–1097), the GAD-7 is routinely paired with depression and somatic symptom instruments—such as the PHQ-2 / PHQ-9 and PHQ-15—inside behavioral health therapy intake forms and biopsychosocial assessments.
What Is the GAD-7 Scale and How Is It Used in Clinical Research and Healthcare?
The GAD-7 asks respondents how often during the last 2 weeks they have been bothered by seven core anxiety symptoms derived from the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for Generalized Anxiety Disorder. Each of the seven items is scored on a 4-point Likert frequency scale:
- 0 points: Not at all
- 1 point: Several days
- 2 points: More than half the days
- 3 points: Nearly every day
Summing the seven items yields a GAD-7 Total Score ranging from 0 to 21. A supplementary eighth item (unscored in the 0–21 total) asks respondents who checked off any problems how difficult those problems have made it to do their work, take care of things at home, or get along with other people (Not difficult at all, Somewhat difficult, Very difficult, or Extremely difficult) to assess functional impairment.
GAD-7 Severity Thresholds and Psychometric Validation
In Spitzer et al.’s foundational validation study across 2,740 adult patients in 15 U.S. primary care clinics (including 965 patients who underwent independent structured mental health professional interviews), the GAD-7 demonstrated an internal consistency of Cronbach’s α = 0.92 and a test-retest intraclass correlation of 0.83:
| GAD-7 Total Score Bracket | Anxiety Severity Classification | Psychometric Benchmark & Clinical Action |
|---|---|---|
| 0 – 4 | Minimal Anxiety | Below clinical threshold; routine observation |
| 5 – 9 | Mild Anxiety | Watchful waiting, psychoeducation, and repeat GAD-7 reassessment at follow-up |
| 10 – 14 | Moderate Anxiety (Optimal Screening Cutoff ≥ 10) | At cutoff ≥ 10, sensitivity is 89% and specificity is 82% for Generalized Anxiety Disorder; warrants structured diagnostic evaluation and consideration of psychotherapy (e.g., CBT) and/or pharmacotherapy |
| 15 – 21 | Severe Anxiety | High probability of active anxiety disorder with marked functional impairment; active treatment (psychotherapy, pharmacotherapy, or combined therapy) indicated |
Subsequent validation by Kroenke et al. in Annals of Internal Medicine (2007;146(5):317–325) demonstrated that a GAD-7 cutoff score of ≥ 10 (or ≥ 8 in general anxiety screening) also performs well as a broad primary care screener for three additional common anxiety disorders: Panic Disorder (sensitivity 74%, specificity 81% at ≥10), Social Anxiety Disorder (sensitivity 72%, specificity 80% at ≥10), and Post-Traumatic Stress Disorder (PTSD) (sensitivity 66%, specificity 81% at ≥10).
What Standards or Regulatory Requirements Govern the GAD-7 Scale?
In clinical research governance and healthcare quality measurement, the GAD-7 is governed by clear copyright, licensing, and trial endpoint rules:
- Public Domain Licensing Status: Although developed by Drs. Spitzer, Williams, Kroenke, and colleagues with an educational grant from Pfizer Inc., the copyright formerly held by Pfizer Inc. was placed in the public domain; no permission or licensing fee is required to reproduce, translate, display, or distribute the GAD-7 in paper or electronic systems.
- Minimal Clinically Important Difference (MCID) in Clinical Trials: In longitudinal randomized controlled trials and measurement-based behavioral health care, a change of ≥ 4 points on the GAD-7 total score (or a ≥ 50% reduction from baseline score) is widely used to define clinically meaningful treatment response, while a score of < 5 defines clinical remission.
How Does the GAD-7 Scale Integrate with EHR and Health Informatics Workflows?
To support automated pre-visit mobile intake, telehealth screening, and longitudinal graphing inside the electronic health record (EHR), the Regenstrief Institute standardized the entire GAD-7 instrument in LOINC and HL7 FHIR:
| GAD-7 Item / Concept | LOINC Code | Official LOINC Component Name |
|---|---|---|
| Complete Panel Header | 69737-5 |
Generalized anxiety disorder 7 item (GAD-7) |
| Item 1 | 69725-0 |
Feeling nervous, anxious or on edge in last 2 weeks |
| Item 2 | 68509-9 |
Not being able to stop or control worrying in last 2 weeks |
| Item 3 | 69733-4 |
Worrying too much about different things in last 2 weeks |
| Item 4 | 69734-2 |
Trouble relaxing in last 2 weeks |
| Item 5 | 69735-9 |
Being so restless that it is hard to sit still in last 2 weeks |
| Item 6 | 69689-8 |
Becoming easily annoyed or irritable in last 2 weeks |
| Item 7 | 69736-7 |
Feeling afraid as if something awful might happen in last 2 weeks |
| GAD-7 Total Score (0–21) | 70274-6 |
Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] |
| Functional Difficulty Item | 69726-8 |
How difficult have these problems made it for you to do your work, take care of things at home, or get along with other people |
Using the HL7 FHIR Structured Data Capture (SDC) specification, digital patient intake apps render LOINC 69737-5 as a FHIR Questionnaire, compute the sum across the seven answer options (LOINC Answer List LL358-3), and write both the QuestionnaireResponse and a discrete FHIR Observation (LOINC 70274-6) into the EHR flowsheet prior to the clinician’s encounter.
Frequently Asked Questions
What is the GAD-7 scale and how is it used in clinical research and healthcare?
The GAD-7 (Generalized Anxiety Disorder-7) scale is a validated 7-item self-report patient-reported outcome measure (PROM) developed by Robert L. Spitzer, Kurt Kroenke, Janet B. W. Williams, and Bernd Löwe (Archives of Internal Medicine, 2006) to screen for generalized anxiety disorder and measure anxiety symptom severity over the preceding two weeks on a 0 to 21 point scale.
What standards or regulatory requirements govern the GAD-7 scale?
Developed with an educational grant from Pfizer Inc., the GAD-7 scale is placed in the public domain (no permission or royalty required to reproduce, translate, or distribute). Its items align with DSM-IV/DSM-5 diagnostic criteria for Generalized Anxiety Disorder, and its severity thresholds (5 = mild, 10 = moderate/clinical screening cutoff, 15 = severe) serve as standard outcome endpoints in behavioral health clinical trials and measurement-based care.
How does the GAD-7 scale integrate with EHR and health informatics workflows?
In health informatics, the GAD-7 is standardized under Regenstrief LOINC Panel 69737-5 (with individual items LOINC 69725-0 through 69736-7 and total score LOINC 70274-6) and exchanged via HL7 FHIR Questionnaire and QuestionnaireResponse resources for automated pre-visit mobile intake and telehealth administration.
Sources
- Spitzer RL, Kroenke K, Williams JBW, Löwe B. “A brief measure for assessing generalized anxiety disorder: the GAD-7.” Archives of Internal Medicine. 2006;166(10):1092–1097. https://pubmed.ncbi.nlm.nih.gov/16717171/
- Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B. “Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection.” Annals of Internal Medicine. 2007;146(5):317–325. https://pubmed.ncbi.nlm.nih.gov/17339617/
- Regenstrief Institute. LOINC 69737-5 — Generalized anxiety disorder 7 item (GAD-7) Panel. https://loinc.org/69737-5/
